Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Meeting to commence at 9.30 am on Tuesday 14th September 2021

via Zoom (Meeting ID: 885 2181 3733 Passcode: 5LDwp4)

AGENDA

To protect commercial confidentiality the meeting will not open to the public until item 9 of the agenda

		Enclosure
1.	**Welcome and introduction**	
2.	**Apologies**	
3.	**Declarations of interest**	
4.	**Minutes of the previous meeting**	**1**/AWMSG/0921
5.	**Appraisal 1: Full (Wales Patient Access Scheme) Nitisinone (Orfadin®)** for the treatment of adult patients with alkaptonuria	**2**/AWMSG/0921 Appendices
6.	**Appraisal 2: Full Submission (Patient Access Scheme) Everolimus (Votubia®)** as adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC)	**3**/AWMSG/0921 Appendices
7.	**Appraisal 3: Full Submission (Wales Patient Access Scheme) Amikacin liposomal (Arikayce®)** for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis	**4**/AWMSG/0921 Appendices
8.	**Appraisal 4: Limited Submission (Wales Patient Access Scheme) Dolutegravir (Tivicay®)** for the treatment of HIV-1 infected adults, adolescents and children aged at least 4 weeks weighing at least 3 kg, in combination with other antiretrovirals	**5**/AWMSG/0921 Appendices
	The meeting will open to the public	
9.	**Appraisal 5: Paediatric licence extension submission Etravirine (Intelence®)** in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 2 to <6 years of age	**6**/AWMSG/0921 Appendices

The outcome of the appraisals will be uploaded to the AWMSG website after the meeting. The applicant company will have ten working days to accept the decision or lodge a request for a review which should be sent to the AWMSG Chair via AWTTC. AWMSG's recommendation will be forwarded to Welsh Government for ratification following acceptance of the outcome by the applicant company or after the ten-day deadline has expired – whichever is sooner. Welsh Government takes account of the AWMSG recommendation when making the final decision on the availability of the medicine in NHS Wales.

Welcome: Powys Teaching UHB

10.	**Chairman's report**	
11.	**NPI Quarterly report**	**7**/AWMSG/0921
12.	**AWMSG Five-Year Medicines Strategy 2018-2023 update report**	**8**/AWMSG/0921
13.	**Feedback from the AWPAG meeting held 30th June 2021**	**9**/AWMSG/0921
14.	**Wales Advice on SGLT-2i Inhibitors in Type 2 Diabetes and Cardiovascular Disease**	**10**/AWMSG/0921
15.	**Tramadol Educational Resources (2021 review)**	**11**/AWMSG/0921
16.	**National Pharmacogenetics Service for Wales**	**12/**AWMSG/0921
17.	**Any other business**	

Date and time of next meeting: Wednesday 13th October 2021